Exhaled condensate microbial bacterial genus combination, kit and its application in predicting cough after COVID-19 infection
By detecting specific microbial genus combinations in the exhaled condensate after COVID-19 infection, we predict cough after COVID-19 infection, solving the problem of insufficient sensitivity and specificity of cough predicted after COVID-19 infection in the existing technology, and achieving efficient prediction results , providing a strong reference for clinical practice.
Patent Information
- Application Number
- CN202410208549.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-26
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-02-26
AI Technical Summary
The existing technology has not yet effectively discussed the microbial changes in exhaled condensate in healthy adults after the infection of the new coronavirus Omicron, and its relationship with chronic cough symptoms. It is difficult to predict cough after the new coronavirus infection with high sensitivity and high specificity.
A combination of exhaled condensate microbial bacteria, including Streptococcus, Haemophilus, Coloriformis, Neisseria, Rochetella, Genosum, and Fusobacteria, was proposed through the 16S rRNA gene V3- V4 variable region-specific amplification primers detect the relative content of these bacterial genus, and calculate the probability of coughing after COVID-19 infection. If the probability is greater than 0.62, it is predicted to be coughing after COVID-19 infection.
High sensitivity and specificity prediction of cough after COVID-19 infection has been achieved, providing a strong reference for clinical practice. The AUC of the combined marker is 0.951, and the sensitivity and specificity are 88.9%.
Smart Images

Figure CN117965772B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a combination of exhaled condensate microorganisms, a kit, and their application in predicting cough after COVID-19 infection. Background Art
[0002] As the novel coronavirus continues to spread around the world, more and more patients have reported persistent and long-term symptoms, including those lasting at least 2 months, and chronic cough is one of the most common respiratory symptoms associated with COVID-19. A comprehensive understanding of the long-term health effects and potential risk factors after infection with the novel coronavirus Omicron strain is critical to public health.
[0003] Exhaled breath condensate (EBC) samples are collected non-invasively and contain a mixture of water vapor and respiratory aerosols. They are an easily accessible biological specimen that can be collected from healthy people and patients. Because its contents include endogenous microorganisms, the microorganisms in EBC are associated with patient disease and recovery. EBC has been used in multiple clinical and translational studies, such as monitoring asthma, allergies, medication use, inflammation, oxidative stress, occupational exposure, and public health. Metabolites, as regulators of airway inflammatory responses and diseases, may play an important role in the occurrence and development of diseases. However, the use of microorganisms in EBC for the evaluation of healthy adults before and after Omicron infection has not been well explored, and their relationship with chronic inflammation and cough symptoms remains unclear. Therefore, it is of great clinical significance to explore the dynamic changes in the respiratory microbiome of healthy adults before and after Omicron infection to determine its relationship with recovery and cough symptoms. Summary of the invention
[0004] The purpose of the present invention is to propose a combination of exhaled condensate metabolite markers. Through the combination of markers, high-sensitivity and high-specificity prediction of cough after COVID-19 infection can be achieved, providing a powerful reference for clinical prediction.
[0005] In view of this, the scheme of the present invention is as follows:
[0006] The first aspect of the present invention is to propose a combination of exhaled condensate microbial genera for predicting cough after COVID-19 infection, including Streptococcus, Haemophilus, Achromobacter, Neisseria, Roseburia, Gemini and Fusobacterium.
[0007] The second aspect of the present invention is to propose the use of a reagent for detecting the combination of microbial genus in the exhaled condensate described in the first aspect in the preparation of a kit for predicting cough after COVID-19 infection.
[0008] Furthermore, the detection reagent includes 16S rRNA gene V3-V4 variable region specific amplification primers.
[0009] Preferably, the nucleotide sequence of the primer is shown in SEQ ID NO: 1-2.
[0010] Furthermore, the kit is used to predict the coughing process after COVID-19 infection and comprises the following steps:
[0011] 1) extracting a solution of a sample of exhaled condensate from a subject, and detecting the relative content a of Streptococcus, the relative content b of Haemophilus, the relative content c of Achromobacter, the relative content d of Neisseria, the relative content e of Roseburia, the relative content f of Geminicoccus, and the relative content g of Fusobacterium in the extract;
[0012] 2) Calculate the probability of coughing after COVID-19 infection Prob. If Prob>0.62, it is predicted that the subject will cough after COVID-19 infection. The calculation method of the probability of coughing after COVID-19 infection is: Prob=1 / (1+e -X ),in:
[0013] X=-0.026a*10 3 +0.009b*10 3 +0.016c*10 3 -0.083d*10 3 +0.096e*10 3 +0.57f*10 3 +
[0014] 0.083g*10 3 -12.527.
[0015] The third aspect of the present invention is to propose a system for predicting cough after COVID-19 infection, comprising:
[0016] Sample collection and processing unit: used to collect the exhaled condensate of the test subject and process it to obtain the extract sample;
[0017] Detection unit: used to detect the relative content a of Streptococcus, the relative content b of Haemophilus, the relative content c of Achromobacter, the relative content d of Neisseria, the relative content e of Roseburia, the relative content f of Geminicoccus, and the relative content g of Fusobacterium in the extract sample;
[0018] Prediction unit: used to calculate the probability Prob of coughing after COVID-19 infection. If Prob>0.62, it is predicted that the subject will cough after COVID-19 infection. The calculation method of the probability of coughing after COVID-19 infection is: Prob=1 / (1+e -X ), where: X = -0.026a*10 3 +0.009b*10 3 +0.016c*10 3 -0.083d*103 +0.096e*10 3 +0.57f*10 3 +0.083g*10 3 -12.527.
[0019] Furthermore, the detection unit designs specific amplification primers for detection based on the V3-V4 variable region of the 16S rRNA gene.
[0020] Preferably, the nucleotide sequence of the primer is shown in SEQ ID NO: 1-2.
[0021] Compared with the prior art, the beneficial effects of the present invention include but are not limited to:
[0022] The metabolites indoleacetic acid and methylglutamate in the exhaled condensate provided by the present invention can be used in combination to predict patients with cough after COVID-19 infection; through the combined markers involved in the present invention, high sensitivity and high specificity prediction of cough after COVID-19 infection can be achieved, providing a powerful reference for clinical prediction. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.
[0024] Figure 1 : This is the ROC curve of the combined marker in predicting the non-cough group and the cough group in the embodiment of the present invention.
[0025] Figure 2 This is a graph showing the accuracy of the combined markers in predicting the non-cough group and the cough group in an embodiment of the present invention. DETAILED DESCRIPTION
[0026] The following provides definitions of some terms used in this specification. Unless otherwise specified, all terms used herein are generally understood by those skilled in the art to which this solution belongs.
[0027] The present invention identifies seven microbial genera with high contents in exhaled condensate, specifically Streptococcus, Haemophilus, Achromobacter, Neisseria, Roseburia, Geminicoccus, and Fusobacterium, all of which are important microorganisms in human exhaled condensate. The present invention combines the above seven microorganisms for the first time and applies them to the prediction of cough after COVID-19 infection.
[0028] The method used to predict cough after COVID-19 infection is as follows:
[0029] (1) Exhaled condensate sample pretreatment method:
[0030] The exhaled condensate sample was thawed at 4°C, 200 μL of it was taken, and 800 μL of methanol extract containing internal standard was added to precipitate protein: vortex for 30-90s, let stand for 15-30mins, centrifuge at 10000-14000×g for 10-15mins at 4°C, and the supernatant was freeze-dried; 50uL of 10-20% (v / v) methanol aqueous solution was added, and centrifuged at 10000-14000×g for 10-15mins at 4°C, and the supernatant was taken for sequencing analysis.
[0031] (2) PCR amplification and sequencing library construction to detect target microorganisms:
[0032] The 16S rRNA gene V3-V4 variable region was amplified by PCR using the upstream primer 338F and the downstream primer 806R carrying the Barcode sequence. The PCR reaction system was: 4 μL of 5×TransStart FastPfu buffer, 2 μL of 2.5 mM dNTPs, 0.8 μL of upstream primer (5 uM), 0.8 μL of downstream primer (5 uM), 0.4 μL of TransStart FastPfu DNA polymerase, and 10 ng of template DNA, which was made up to 20 μL.
[0033] 338F: 5'-ACTCCTACGGGAGGCAGCAG-3' (SEQ ID NO: 1);
[0034] 806R: 5'-GGACTACHVGGGTWTCTAAT-3' (SEQ ID NO: 2).
[0035] The amplification procedure was as follows: 95°C pre-denaturation for 3 min, 27 cycles (95°C denaturation for 30 s, 55°C annealing for 30 s, 72°C extension for 30 s), then 72°C stable extension for 10 min, and finally storage at 4°C (PCR instrument: ABI 9700). Each sample was repeated three times. The PCR products of the same sample were mixed and recovered using 2% agarose gel and purified. The size of the band fragments was detected by 2% agarose gel electrophoresis and the size of the band fragments was detected by Quantus TM The recovered products were detected and quantified using a Fluorometer (Promega, USA).
[0036] The purified PCR products were constructed using the NEXTFLEX Rapid DNA-Seq Kit (Bioo Scientific, Austin, Texas, USA): (1) adapter ligation; (2) using magnetic beads to screen and remove adapter self-ligation fragments; (3) using PCR amplification to enrich the library template; (4) using magnetic beads to recover the PCR products to obtain the final library. Sequencing was performed using the Illumina PE300 / PE250 platform (Shanghai Meiji Biopharmaceutical Technology Co., Ltd.). The raw data were uploaded to the NCBI SRA database.
[0037] (3) Judgment model based on sequencing data:
[0038] The obtained data were analyzed by binary logistic regression using SPSS software, and the regression equation obtained by the constructed model is as follows:
[0039] X=-0.026a*10 3 +0.009b*10 3 +0.016c*10 3 -0.083d*10 3 +0.096e*10 3 +0.57f*10 3 +
[0040] 0.083g*10 3 -12.527.
[0041] Prob(cough) = 1 / (1+e -X )
[0042] Exhaled condensate samples were collected from the subjects, microorganisms were extracted, and the contents of Streptococcus, Haemophilus, Achromobacter, Neisseria, Roseburia, Geminicoccus, and Fusobacterium in the exhaled condensate samples were detected. Prob (tuberculous pleurisy) was the probability of predicting cough, and Cutoff = 0.62, that is, when the Prob (cough) value was greater than 0.62, cough after COVID-19 infection was predicted.
[0043] The model has good predictive ability for cough and non-cough after COVID-19 infection (see Figure 2 ), the AUC of the combined marker was 0.951, the sensitivity was 88.9%, and the specificity was 88.9%.
[0044] Example 1
[0045] 1. Before collecting exhaled condensate samples, volunteers were required to sign an informed consent form.
[0046] Inclusion criteria: 1) age ≥ 18 years; 2) stable EBC samples obtained before SARS-CoV-2 infection; 3) no history of tumor or other serious, uncontrolled diseases; 4) complete clinical data; 5) a signed and dated written informed consent was obtained before participation.
[0047] Exclusion criteria were: 1) uncertain COVID-19 diagnosis, 2) missing information, 3) withdrawal of consent, and 4) living outside Wuhan and unwilling to travel to Wuhan for further examination.
[0048] Exhaled condensate samples were used under the same conditions: exhaled condensate samples were collected from 18 healthy people before they were infected with the new coronavirus, of which 9 did not develop cough after infection, and 9 had cough after infection, which lasted for at least 1 month; 150 ml of the patient's exhaled condensate was collected, the exhaled condensate was separated within half an hour, and stored in a -80°C refrigerator for inspection.
[0049] 2. Analytical methods
[0050] 2.1 Pretreatment of exhaled condensate samples
[0051] The exhaled condensate sample was thawed at 4°C, 200 μL of it was taken, and 800 μL of methanol extract containing internal standard was added to precipitate protein: vortexed for 30-90s, allowed to stand for 15-30mins, centrifuged at 10000-14000×g for 10-15mins at 4°C, and the supernatant was freeze-dried; 50uL of 10-20% (v / v) methanol aqueous solution was added, and the sample was centrifuged at 12000×g for 15mins at 4°C, and the supernatant was taken for subsequent analysis.
[0052] 2.2 PCR amplification and sequencing library construction
[0053] The DNA extracted above was used as a template, and the upstream primer 338F and the downstream primer 806R carrying the Barcode sequence were used to perform PCR amplification on the variable region of the 16S rRNA gene V3-V4. The PCR reaction system was: 4 μL of 5×TransStart FastPfu buffer, 2 μL of 2.5 mM dNTPs, 0.8 μL of upstream primer (5 uM), 0.8 μL of downstream primer (5 uM), 0.4 μL of TransStartFastPfu DNA polymerase, 10 ng of template DNA, and the amount was supplemented to 20 μL. The amplification procedure was as follows: 95°C pre-denaturation for 3 min, 27 cycles (95°C denaturation for 30 s, 55°C annealing for 30 s, 72°C extension for 30 s), then 72°C stable extension for 10 min, and finally stored at 4°C (PCR instrument: ABI 9700). Each sample was repeated three times. The PCR products of the same sample were mixed and recovered using 2% agarose gel and purified. The size of the band fragments was detected by 2% agarose gel electrophoresis and the size of the band fragments was detected by Quantus TM The recovered products were detected and quantified using a Fluorometer (Promega, USA).
[0054] use The purified PCR products were used for library construction using Rapid DNA-Seq Kit (Bioo Scientific, Austin, Texas, USA): (1) linker ligation; (2) using magnetic beads to screen and remove linker self-ligated fragments; (3) using PCR amplification to enrich the library template; (4) using magnetic beads to recover the PCR products to obtain the final library. Sequencing was performed using Illumina's PE300 / PE250 platform (Shanghai Meiji Biopharmaceutical Technology Co., Ltd.). The raw data were uploaded to the NCBI SRA database.
[0055] 2.3 Exhaled condensate test results and auxiliary prediction methods
[0056] The relative contents of the seven bacterial communities were substituted into the regression equation to calculate the probability. The cutoff value used was 0.62, that is, if the probability of the combined marker was greater than 0.62, it was considered to be a cough after COVID-19 infection. The AUC of the combined marker was 0.951, and the sensitivity and specificity were also relatively high, at 88.9% and 88.9% respectively ( Figure 1 , Figure 2 ).
[0057] Although the present invention is disclosed as above, the protection scope of the present invention is not limited thereto. Those skilled in the art may make various changes and modifications without departing from the spirit and scope of the present invention, and these changes and modifications will fall within the protection scope of the present invention.
Claims
1. The use of a reagent for detecting a combination of microbial genus in exhaled condensate in the preparation of a kit for predicting cough after COVID-19 infection, characterized in that: The microbial genus combination consists of Streptococcus, Haemophilus, Achromobacter, Neisseria, Roseburia, Geminicoccus and Fusobacterium; the detection reagent includes 16S rRNA gene V3-V4 variable region specific amplification primers, and the nucleotide sequence of the primers is shown in SEQ ID NO: 1-2; The kit is used to predict the coughing process after COVID-19 infection and includes the following steps: Take the exhaled condensate sample of the subject to extract the solution, and detect the relative content a of Streptococcus, the relative content b of Haemophilus, the relative content c of Achromobacter, the relative content d of Neisseria, the relative content e of Roseburia, the relative content f of Geminicoccus, and the relative content g of Fusobacterium in the extract; Calculate the probability of coughing after COVID-19 infection Prob. If Prob>0.62, it is predicted that the subject will cough after COVID-19 infection. The calculation method of the probability of coughing after COVID-19 infection is: Prob = 1 / (1+e -X ), where X=-0.026a*10 3 +0.009b*10 3 +0.016c*10 3 -0.083d*10 3 +0.096e*10 3 +0.57f*10 3 + 0.083g*10 3 -12.527。
